Effects of ulinastatin on perioperative inflammatory response and pulmonary function in cardiopulmonary bypass patients

American Journal of Therapeutics

Volumn 23, Issue 6, 2016, Pages e1680-e1689

  Pang, Xin Yan ^a   Fang, Chang Cun ^a   Chen, Yuan Yuan ^a   Liu, Kai ^a   Song, Guang Min ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Anti inflammatory; Arterial blood gas; Cardiopulmonary bypass; Inflammatory response; Proinflammatory cytokines; Pulmonary function; Respiratory function; Ulinastatin

Indexed keywords

AUTACOID; CYTOKINE; GLYCOPROTEIN; INTERLEUKIN DERIVATIVE; TUMOR NECROSIS FACTOR; ULINASTATIN;

ACUTE LUNG INJURY; ADOLESCENT; ADULT; AGED; BIOSYNTHESIS; BLOOD; BLOOD GAS ANALYSIS; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; INFLAMMATION; LUNG FUNCTION TEST; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PERIOPERATIVE PERIOD; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; YOUNG ADULT;

ACUTE LUNG INJURY; ADOLESCENT; ADULT; AGED; BLOOD GAS ANALYSIS; CARDIOPULMONARY BYPASS; CYTOKINES; FEMALE; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKINS; MALE; MIDDLE AGED; PERIOPERATIVE PERIOD; RESPIRATORY FUNCTION TESTS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84995803073     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000243     Document Type: Article

References (44)

1. Wan S, Yim AP. Multi-organ protection during open heart surgery. Chin Med J (Engl). 2001;114:3-8.
2. Asimakopoulos G. Systemic inflammation and cardiac surgery: an update. Perfusion. 2001;16:353-360.
3. Ng CS, Wan S, Yim AP, et al. Pulmonary dysfunction after cardiac surgery. Chest. 2002;121:1269-1277.
4. Wynne R, Botti M. Postoperative pulmonary dysfunction in adults after cardiac surgery with cardiopulmonary bypass: clinical significance and implications for practice. Am J Crit Care. 2004;13:384-393.
5. Clark SC. Lung injury after cardiopulmonary bypass. Perfusion. 2006;21:225-228.
6. Apostolakis E, Filos KS, Koletsis E, et al. Lung dysfunction following cardiopulmonary bypass. J Card Surg. 2010;25:47-55.
7. Wang DJ, Liu JX, Yin BL. Protective effects of ulinastatin on the lung injury during cardiopulmonary bypass [in Chinese]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2005;30: 670-672.
8. Zhou Q, Wang G, Gao C, et al. Effect of ulinastatin on perioperative inflammatory response to coronary artery bypass grafting with cardiopulmonary bypass [in Chinese]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010;35: 107-110.
9. Zhang ZF, Yang N, Zhao G, et al. Preventive effect of ulinastatin and gabexate mesylate on post-endoscopic retrograde cholangiopancreatography pancreatitis. Chin Med J (Engl). 2010;123:2600-2606.
10. Linder A, Russell JA. An exciting candidate therapy for sepsis: ulinastatin, a urinary protease inhibitor. Intensive Care Med. 2014;40:1164-1167.
11. Kawamura Y, Kanai T, Takeshita S, et al. Use of the urinary trypsin inhibitor ulinastatin for acute Kawasaki disease [in Japanese]. Nihon Rinsho. 2014;72:1650-1653.
12. Xu L, Ren B, Li M, et al. Ulinastatin suppresses systemic inflammatory response following lung ischemia-reperfusion injury in rats. Transplant Proc. 2008;40:1310-1311.
13. Fang Y, Xu P, Gu C, et al. Ulinastatin improves pulmonary function in severe burn-induced acute lung injury by attenuating inflammatory response. J Trauma. 2011;71: 1297-1304.
14. Nakanishi K, Takeda S, Sakamoto A, et al. Effects of ulinastatin treatment on the cardiopulmonary bypassinduced hemodynamic instability and pulmonary dysfunction. Crit Care Med. 2006;34:1351-1357.
15. Park JB, Kim SH, Lee SA, et al. Effects of ulinastatin on postoperative blood loss and hemostasis in atrioventricular valve surgery with cardiopulmonary bypass. Korean J Thorac Cardiovasc Surg. 2013;46:185-191.
16. Song J, Park J, Kim JY, et al. Effect of ulinastatin on perioperative organ function and systemic inflammatory reaction during cardiac surgery: a randomized doubleblinded study. Korean J Anesthesiol. 2013;64:334-340.
17. Glas J, Seiderer J, Bues S, et al. IRGM variants and susceptibility to inflammatory bowel disease in the German population. PLoS One. 2013;8:e54338.
18. Warren JS, Ward PA, Johnson KJ. Tumor necrosis factor: a plurifunctional mediator of acute inflammation. Mod Pathol. 1988;1:242-247.
19. Mannel DN, Echtenacher B. TNF in the inflammatory response. Chem Immunol. 2000;74:141-161.
20. Harada A, Sekido N, Akahoshi T, et al. Essential involvement of interleukin-8 (il-8) in acute inflammation. J Leukoc Biol. 1994;56:559-564.
21. Kawamura T, Wakusawa R, Okada K, et al. Elevation of cytokines during open heart surgery with cardiopulmonary bypass: participation of interleukin 8 and 6 in reperfusion injury. Can J Anaesth. 1993;40:1016-1021.
22. Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothorac Surg. 2002;21: 232-244.
23. Murphy GJ, Angelini GD. Side effects of cardiopulmonary bypass: what is the reality? J Card Surg. 2004;19: 481-488.
24. Pasnik J. The significance of neutrophil in inflammatory response after cardiac surgery with cardiopulmonary bypass [in Polish]. Wiad Lek. 2007;60:171-177.
25. Cao YZ, Tu YY, Chen X, et al. Protective effect of ulinastatin against murine models of sepsis: inhibition of TNF-αlpha and IL-6 and augmentation of IL-10 and IL-13. Exp Toxicol Pathol. 2012;64:543-547.
26. Sugita T, Watarida S, Katsuyama K, et al. Effect of a human urinary protease inhibitor (ulinastatin) on respiratory function in pediatric patients undergoing cardiopulmonary bypass. J Cardiovasc Surg (Torino). 2002;43: 437-440.
27. Xu CE, Zou CW, Zhang MY, et al. Effects of high-dose ulinastatin on inflammatory response and pulmonary function in patients with type-A aortic dissection after cardiopulmonary bypass under deep hypothermic circulatory arrest. J Cardiothorac Vasc Anesth. 2013;27:479-484.
28. Bingyang J, Jinping L, Mingzheng L, et al. Effects of urinary protease inhibitor on inflammatory response during on-pump coronary revascularisation. Effect of ulinastatin on inflammatory response. J Cardiovasc Surg (Torino). 2007;48:497-503.
29. Zhang Y, Zeng Z, Cao Y, et al. Effect of urinary protease inhibitor (ulinastatin) on cardiopulmonary bypass: a meta-analysis for China and Japan. PLoS One. 2014;9: e113973.
30. Park KH, Lee KH, Kim H, et al. The anti-inflammatory effects of ulinastatin in trauma patients with hemorrhagic shock. J Korean Med Sci. 2010;25:128-134.
31. Oh SY, Kim JC, Choi YS, et al. Effects of ulinastatin treatment on myocardial and renal injury in patients undergoing aortic valve replacement with cardiopulmonary bypass. Korean J Anesthesiol. 2012;62:148-153.
32. Balk RA. Systemic inflammatory response syndrome (SIRS): where did it come from and is it still relevant today? Virulence. 2014;5:20-26.
33. Yang Q, Liu X, Liu M, et al. Ulinastatin-mediated protection against zymosan-induced multiple organ dysfunction in rats. Biologicals. 2010;38:552-556.
34. Gao C, Li R, Wang S. Ulinastatin protects pulmonary tissues from lipopolysaccharide-induced injury as an immunomodulator. J Trauma Acute Care Surg. 2012;72: 169-176.
35. Giannessi D, Caselli C, Vitale RL, et al. A possible cardioprotective effect of heat shock proteins during cardiac surgery in pediatric patients. Pharmacol Res. 2003; 48:519-529.
36. Dybdahl B, Wahba A, Haaverstad R, et al. On-pump versus off-pump coronary artery bypass grafting: more heat-shock protein 70 is released after on-pump surgery. Eur J Cardiothorac Surg. 2004;25:985-992.
37. Wang Z, Gall JM, Bonegio RG, et al. Induction of heat shock protein 70 inhibits ischemic renal injury. Kidney Int. 2011;79:861-870.
38. Zhou CY, Zhang ZJ, Luo YJ, et al. Effect of ulinastatin on the expression of heat shock protein 70 and NF-kappaB in lung tissue in rats with paraquat poisoned [in Chinese]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2011;29:280-283.
39. Alat I, Yuksel M, Buket S, et al. The side-effects of cardiopulmonary bypass on the lungs: changes in bronchoalveolar lavage fluids. Perfusion. 2001;16:121-128.
40. Takano H, Inoue K, Shimada A, et al. Urinary trypsin inhibitor protects against liver injury and coagulation pathway dysregulation induced by lipopolysaccharide/ d-galactosamine in mice. Lab Invest. 2009;89:833-839.
41. Ueki M, Taie S, Chujo K, et al. Urinary trypsin inhibitor reduces inflammatory response in kidney induced by lipopolysaccharide. J Biosci Bioeng. 2007;104:315-320.
42. Gao C, Liu Y, Ma L, et al. Protective effects of ulinastatin on pulmonary damage in rats following scald injury. Burns. 2012;38:1027-1034.
43. Yu XY, Fan LL. Effects of different doses of ulinastatin on inflammatory response and pulmonary function after cardiopulmonary bypass [in Chinese]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2009;21:664-667.
44. Jiang YF, Wang WW, Ye WL, et al. Effects of alprostadil and ulinastatin on inflammatory response and lung injury after cardiopulmonary bypass in pediatric patients with congenital heart diseases [in Chinese]. Zhonghua Yi Xue Za Zhi. 2008;88:2893-2897.